A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease

Trial Profile

A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs OMS 721 (Primary)
  • Indications IgA nephropathy; Lupus nephritis
  • Focus Adverse reactions
  • Sponsors Omeros Corporation
  • Most Recent Events

    • 14 Aug 2017 According to an Omeros Corporation media release, data from this trial has been presented at the 54th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress.
    • 14 Aug 2017 Results published in the Omeros Corporation media release.
    • 13 Jun 2017 According to an Omeros Corporation media release, based on the data from this trial the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top